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Abstract
Background—Alcohol and nicotine are largely co-abused. Here, we investigated whether 
concurrent exposure to both addictive drugs influences each other’s consumption and whether 
varenicline attenuates alcohol consumption in the presence of nicotine.
Methods—Marchigian Sardinian alcohol-preferring (msP) rats trained to simultaneously self-
administer oral alcohol (10% v/v) and intravenous nicotine (30 μg/kg/inf.) were used. Additional 
groups of rats were trained to self-administer either alcohol or nicotine. Further, msP rats were 
also trained to self-administer nicotine followed by 22-h/day access to alcohol and water in a two 
bottle free choice paradigm or water alone. The effects of varenicline (0.0, 0.3, 1.0, 3.0 mg/kg, 
p.o.) on alcohol and nicotine consumption was tested.
Results—In a self-administration paradigm, msP rats showed a significantly high levels of 
alcohol and nicotine intake when the drugs were administered alone. However, when access to 
both drugs occurred concomitantly, the number of nicotine infusions self-administered was 
significantly decreased. Nicotine self-administration was markedly reduced by varenicline 
regardless of whether it was self-administered alone or concurrently with alcohol. In a two bottle 
choice test, varenicline significantly decreased nicotine self-administration but had no influence 
on alcohol consumption.
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Conclusion—Varenicline is highly efficacious in decreaasing nicotine self-administration either 
alone or in combination with alcohol. However, varenicline failed to influence both operant 
responding for alcohol and home-cage alcohol drinking in msP animals. Taken together, our 
findings suggest that the effects of varenicline could be specific to nicotine under conditions 
where excessive alcohol drinking is facilitated by genetic factors as in msP rats.
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1. INTRODUCTION
Alcohol and nicotine are largely co-abused. Epidemiological data indicate that most 
alcoholics are also smokers and that smokers have an increased risk of developing alcohol 
use disorders (DiFranza and Guerrera, 1990; Miller and Gold, 1998). Nicotine dependence 
appears to be more severe in smokers with a history of alcohol dependence and it is more 
difficult to quit tobacco use when the smoking habit is associated with alcohol drinking 
(Romberger and Grant, 2004). In addition, the co-occurrence of nicotine and alcohol 
dependence leads to increased morbidity and mortality, with tobacco-related disease being 
the leading cause of death in recovering alcohol-dependent patients (Hurt et al., 1996). This 
strong association observed between alcohol and nicotine addiction is due to a variety of 
factors. First, psychosocial factors, as childhood maltreatment, are robust and common risk 
factors for the occurrence of the two disorders (Mingione et al., 2012). Second, in most 
countries alcohol and tobacco consumption are both legally accepted, hence making them 
widely available to the population (Funk et al., 2006). Lastly, common molecular and 
cellular mechanisms (Doyon et al., 2013; Hendrickson et al., 2013) may subserve their use, 
shaping the risks of co-abuse of these two highly addictive drugs. For example, both alcohol 
and nicotine activate the mesolimbic dopamine (DA) reward pathway and combining the 
two might yield additive or synergistic motivational effects (Tizabi et al., 2002).
While nicotine primarily acts via nicotinic acetylcholine receptors (nAChRs), alcohol acts 
upon a wide range of receptors and molecular substrates, including nAChRs. Specifically, it 
has been demonstrated that development of nicotine dependence may result from initial 
activation of DA neurons via nAChRs containing α4 and β2 subunits (Picciotto et al., 1998; 
Tapper et al., 2004). On the other hand, alcohol can also increase acetylcholine release into 
the ventral tegmental area (Larsson et al., 2005), driving activation of DA neurons through 
nAChRs. In this regard, a role of α4 nAChR subunits in alcohol reward has been proposed 
(Liu et al., 2013). It has also been shown that nicotine may increase alcohol’s reinforcing 
properties via upregulation of nAChRs, thus setting the condition for enhanced vulnerability 
to consume alcohol (Hendrickson et al., 2013). Recently, the α6 nAChR subunit has also 
been indicated as an important player in the response to nicotine and alcohol co-exposure in 
neurons of the ventral tegmental area (Engle et al., 2015). Based on these findings, nAChRs 
have been proposed to be targets for the development of novel and possibly more effective 
pharmacological interventions not only for the treatment of nicotine, but also alcohol 
addiction (Chatterjee and Bartlett, 2010; Hendrickson et al., 2013).
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Varenicline (Chantix) is currently the most effective pharmacotherapy for promoting 
smoking cessation (Jorenby et al., 2006). Although hypothesized to reduce smoking via 
partial activation of the α4β2 nAChRs, varenicline also shows partial or full agonist activity 
at other nAChR subtypes including those containing α6, α3β4 and α7 subunits (Chatterjee et 
al., 2011; Cippitelli et al., 2015c; Mihalak et al., 2006; Rollema et al., 2007). This complex 
pharmacological profile reflects complex actions of varenicline in vivo. If, on the one hand, 
it reduces nicotine consumption, on the other hand, varenicline acts as a primary reinforcer 
and elicits reinstatement of nicotine seeking in rats (Cippitelli et al., 2015c). Pre-clinical 
studies have demonstrated that varenicline decreases both operant and home cage alcohol 
self-administration in rodents (Kamens et al., 2010; Steensland et al., 2007) and, recently, 
clinical evidence indicating reduced drinking in a population of heavy-drinking smokers or 
primary alcoholic patients treated with varenicline have started to emerge (Childs et al., 
2012; Fucito et al., 2011; Litten et al., 2013; McKee et al., 2009; Mitchell et al., 2012). 
These well-documented anti-alcohol properties of varenicline seem to be dependent on the 
activation of α4 nAChRs (Hendrickson et al., 2010). In contrast, α7 (Kuzmin et al., 2009) 
and α3β4 nAChRs (Carnicella et al., 2010; Cippitelli et al., 2015b) may not be involved in 
alcohol reinforcement. Consistent with this literature, we have recently demonstrated the 
efficacy of varenicline in decreasing alcohol self-administration at doses that also decreased 
nicotine self-administraton in an operant co-administration paradigm (Cippitelli et al., 
2015c). A similar response was observed when the effects of varenicline were tested on 
alcohol and food-maintained responding in a similar concurrent access procedure (Ginsburg 
and Lamb, 2013).
Genetic factors are known to contribute to alcohol and nicotine co-abuse (Dani and Harris, 
2005; Tyndale, 2003). Evidence of common genetic vulnerability traits for nicotine and 
alcohol dependence in humans have been documented (Enoch and Goldman, 2001). For 
instance, data obtained in P rats, a line genetically selected for high alcohol consumption, 
showed that these animals were more sensitive to nicotine (Gordon et al., 1993), consumed 
greater amounts of nicotine intravenously and showed increased vulnerability to alcohol 
relapse (Le et al., 2006) than alcohol non-preferring (NP) rats. Here, we used genetically 
selected marchigian sardinian alcohol preferring (msP) rats, an established animal model of 
excessive alcohol drinking and preference (Ciccocioppo et al., 2006), to investigate whether 
concurrent exposure to alcohol and nicotine influences the intake of either drug. We also 
investigated whether varenicline alters the consumption of alcohol and nicotine in msP 
animals when both drugs are made simultaneously available under operant self-
administration conditions or when nicotine self-administration is followed by home-cage 
access to ethanol. The present study extends our previous investigation in Sprague-Dawley 
rats (Cippitelli et al., 2015c) to evaluate if varenicline may represent a suitable 
pharmacological treatment for alcohol drinking when consumption occurs in conjunction 
with nicotine in animals with innate predisposition to consume high amounts of alcohol. The 
results of this study may be useful to predict if a subpopulation of smokers with a genetic 
predisposition to alcohol abuse may differ in their response to varenicline.
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2. MATERIALS AND METHODS
2.1 Animals
Male genetically selected alcohol-preferring msP rats were used. MsP rats were bred at the 
University of Camerino and housed in groups of two except where specified, in rooms with 
a reverse 12 h light-dark cycle (lights off at 08:30 AM) at a constant temperature of 20± 2°C 
and relative humidity of 45–55%, with free access to tap water and food pellets (4RF18, 
Mucedola, Settimo Milanese, Italy). Experiments were conducted during the dark phase of 
the light/dark cycle. Animals were handled three times before the onset of each experiment. 
All procedures followed the EU Directive for Care and Use of Laboratory Animals.
2.2 Drugs
Varenicline or its vehicle (distilled water) were given orally (p.o.), by gavage. Varenicline 
was prepared from 1-mg tablets (Chantix, Pfizer, Italy). Tablets were crushed in a laboratory 
ceramic mortar. Powder was transferred into 20 ml test tubes where it was suspended in 
distilled water. Test tubes were vortexed before filling the syringe for oral administration. 
Injection volume was 2 ml/kg. Nicotine (Sigma, Milan, Italy) was dissolved in 0.9% saline 
(30 μg/kg/0.1 ml). The solution was neutralized to an isotonic pH (7.4) with NaOH 5M and 
given intravenously (i.v.). Nicotine self-administration doses are reported as free base 
concentrations. Alcohol 10% (v/v) was prepared by dilution of 95% alcohol (F.L. Carsetti 
s.n.c., Camerino, Italy) in water.
2.3 Intravenous surgery
Catheter implantation in the rat jugular vein was performed as previously described (de 
Guglielmo et al., 2013). In brief, animals were anesthetized by intramuscular injection of 
100–150 μl of a solution containing tiletamine chloridrate (58.17mg/ml) and zolazepam 
cloridrate (57.5 mg/ml). Incisions were made to expose the right jugular vein and a catheter 
made from silicon tubing (I.D. =0.020 inches, O.D. =0.037 inches) was subcutaneously 
positioned. After insertion into the vein, the proximal end of the catheter was anchored to 
the muscles underlying the vein with surgical silk. The distal end of the catheter was 
attached to a stainless-steel cannula bent at a 90° angle, inserted in a support made by dental 
cement and covered with a plastic cap. The cannula was connected to the fluid swivel 
system during nicotine self-administration. Catheter patency was confirmed with an 
injection of 0.2–0.3 ml of thiopental sodium (250 mg/ml) solution. Patency of the catheter 
was assumed if there was an immediate loss of reflexes. Self-administration experiments 
began 1 week after surgery. Rats self-administering only alcohol were subjected to a sham 
surgery that involved ligation of the right jugular vein.
2.4 Operant self-administration apparatus
Self-administration of only nicotine or alcohol as well as drug co-administration 
experiments were carried out in operant conditioning chambers (Med Associate, Inc., St. 
Albans, VT) enclosed in light and sound-attenuating, ventilated environmental cubicles. The 
front door and the back wall of the chamber were made of transparent plastic and the other 
walls were opaque metal. Each chamber was equipped with two retractable levers located in 
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the front panel of the chamber to the sides of a drinking receptacle. Levers were extended at 
the beginning of the self-administration sessions. The chambers were also equipped with a 
white house light located near the top of the chamber opposite the lever and white cue lights 
located above the levers. Infusions occurred by means of syringe pumps (Med Associates, 
Inc., St. Albans, VT) and liquid swivels (Instech Solomon, Plymouth Meeting, PA), 
connected to plastic tubing protected by a flexible metal sheath for attachment to the 
external catheter terminus. In the case of self-administration of one reinforcer alone, an 
infusion pump was activated by responses on the right (active) lever, while responses on the 
left (inactive) lever were recorded but did not result in any programmed consequences. 
Activation of the pump resulted in a delivery of 0.1 ml of nicotine or alcohol. During co-
administration of intravenous nicotine and oral alcohol, chambers were equipped with two 
active levers and two infusion pumps, one that delivered iv nicotine (0.1 ml over 5 seconds) 
and one that delivered alcohol (0.1 ml over 1 second) into the drinking receptacle. Thus, 
appropriate responding on the right lever resulted in activation of the pump containing 
nicotine while responding on the left lever resulted in activation of the pump that released 
alcohol, which was connected to the drinking receptacle. A microcomputer controlled the 
delivery of reinforcers, presentation of auditory and visual stimuli and recording of the 
behavioral data. Self-administration sessions were performed starting at 9.30 a.m. which is 1 
hour after the onset of the dark cycle.
2.5 Two-bottle free choice drinking paradigm
Two groups of msP rats were used for this study. Animals were single-housed to provide 
accurate record of home-cage drinking (Ayanwuyi et al., 2013). One group (alcohol-
exposed, N=12) was offered concurrent, continuous access to 10% alcohol solution, water, 
and food pellets. The other group (non-exposed, N=12) had only water and food available. 
Fluids were presented in graduated plastic tubes equipped with stainless-steel drinking 
spouts inserted through two grommets in front of the cage. Alcohol and water tubes were 
refilled daily, 60 min into the dark period of the light/dark cycle. The placement of the 
alcohol bottle was alternated daily to control for side preference. Both groups (exposed vs 
non-exposed) were subjected to a daily 2-h nicotine self-administration session, 5 days a 
week. This procedure was carried out for the whole duration of the experiment (training and 
drug testing). Data are presented as daily alcohol intake (g/kg).
2.6 Self-administration of nicotine alone, alcohol alone or their co-administration in msP 
rats: Effect of varenicline
Three groups of msP rats were used: one group (N=8) was trained to co-administer 10% 
(v/v) alcohol and nicotine (30 μg/kg/inf.) during the same operant session. A second group 
of rats (N=9) was trained to self-administer nicotine alone and the last group (N=10) was 
trained to self-administer alcohol alone. Co-administration of nicotine and alcohol was 
conducted as previously described (Cippitelli et al., 2015c; Le et al., 2010). Following each 
nicotine infusion, a 20-sec time out (TO) period occurred, during which responses at the 
lever that delivered nicotine (right lever) did not lead to programmed consequences. 
Nicotine reinforcements were accompanied by concurrent illumination of the cue light 
above the nicotine-associated lever to signal delivery of nicotine. Alcohol reinforcements 
were accompanied by a flashing house light (0.5 sec on, 0.5 sec off) with a TO period of 10 
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sec during which responses at the lever that delivered alcohol (left lever) did not lead to 
programmed consequences. An intermittent tone (7 kHz, 70 dB) was sounded throughout 
the 60-min session. Self-administration of only nicotine or only alcohol used identical 
conditions as co-administration sessions but only one lever was active. All self-
administration sessions were conducted under a fixed ratio 1 (FR-1) reinforcement schedule. 
Sessions lasted 60 min except where otherwise specified. Nicotine, alcohol and their 
simultaneous self-administration was maintained for 19 days. Following this training period, 
the effect of varenicline (0.3, 1 and 3 mg/kg/2ml) or its vehicle (0 mg/kg/2ml) on operant 
self-administration was tested. Experiments were conducted according to a within-subject 
Latin square counterbalanced design. Varenicline was administered p.o., by gavage, 30 
minutes before the beginning of operant sessions. Testing sessions were conducted every 3–
4 days. The day after the experiment, rats were allowed 1 day off and then a new baseline 
was established over the following 1 or 2 days (Cippitelli et al., 2015b). Data are expressed 
as mean ± S.E.M. number of infusions or rewards for nicotine and alcohol, respectively.
2.7 Nicotine self-administration in msP rats with or without access to alcohol in the two 
bottle choice paradigm: Effect of varenicline
Rats were trained to self-administer nicotine (60 μg/kg/inf.) in daily 2-h sessions. Half of the 
rats were exposed to alcohol daily for 22h, in the two-bottle choice paradigm. The other half 
had water and food but no alcohol available in their home-cages. Nicotine sessions were 
conducted on a FR-1 reinforcement schedule. As described above, each nicotine infusion 
was followed by a 20-sec TO period during which presses on the active lever did not lead to 
any programmed consequences. TO was accompanied by illumination of a cue light located 
above the active lever to signal delivery of the positive reinforcement, while an intermittent 
tone was presented throughout the 2-h session. After 17 days of intravenous nicotine self-
administration followed by alcohol exposure, the effect of varenicline was investigated. Rats 
were treated with varenicline (0.0, 0.3, 1, 3 mg/kg) in a within-subject counterbalanced 
Latin square order 30 min before the start of the nicotine operant session. Immediately after 
the end of the session, rats were returned to their home-cages where alcohol, water and food 
intake was monitored at 2 and 24 h following the onset of alcohol exposure. Experiments 
were performed every three days. The day after drug testing, animals were left undisturbed 
in their home-cages and on the following day a nicotine self-administration baseline was re-
established.
2.8 Statistical analysis
Nicotine or alcohol self-administration alone versus lever pressing on drug co-
administration were analyzed by a two-way ANOVA with “co-administration” used as the 
between-subject factor and “day” as the within-subject factor. A t-test analysis was used to 
compare the baseline levels of lever presses over the last three training days. Effects of 
varenicline on nicotine alone and co-administration, and alcohol alone and co-administration 
were analysed by a two-way ANOVA with “co-administration” used as the between-subject 
factor and “treatment” as the within-subject factor. The same approach was used to analyze 
the effect of varenicline on nicotine self-administration of msP rats in the presence or 
absence of alcohol. In this two-way ANOVA analysis “alcohol exposure” was the between-
subjects factor and “treatment” was the within-subjects factor. Data from the two-bottle free 
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choice experiment were analysed by a two-way ANOVA that used “treatment” and “time” 
as the within-subject factors. The level of significance was set at p<0.05. When appropriate, 
analyses were followed up by Fisher’s least significant difference (LSD) post-hoc test. Prior 
to performing ANOVA’s all data were analyzed to confirm that the assumption of sphericity 
had not been violated using Mauchly’s test of sphericity.
3. RESULTS
3.1 Self-administration of nicotine alone, alcohol alone or their co-administration in msP 
rats: Effect of varenicline
Rats self-administering nicotine alone showed a greater increase in the number of infusions 
self-administered compared to rats co-administering both drugs (Figure 1A). Overall, the 
ANOVA revealed a main effect of administration condition [F(1,17)=6.0, p<0.05] with 
pairwise comparisons showing differences between the nicotine alone and the co-
administration group particularly over the last few operant sessions. The analysis also 
showed an effect of day [F(18,306)=3.04, p<0.001], while the interaction between day and 
administration condition was not statistically significant [F(18,306)=0.71, p=NS]. A t-test 
analysis conducted on the mean number of infusions over the last three training days 
confirmed a significant difference between the mean number of nicotine infusions earned by 
the two groups ([t(17)=2.145, p<0.05], Figure 1B). The overall ANOVA revealed no 
differences [F(1,18)=2.9, NS] in number of lever presses for alcohol in the co-administration 
group compared to the group of animals self-administering only alcohol (Figure 1C). This 
result was confirmed by a t-test conducted on the mean number of alcohol rewards earned 
during the last three operant sessions ([t(18)=0.95, NS], Figure 1D). The ANOVA also 
showed an effect of day [F(18,324)=19.05, p<0.001], but there was no interaction between 
day and co-administration [F(18,324)=1.3, p=NS].
As expected, varenicline significantly decreased nicotine intake independently from alcohol 
availability (Figure 2). Overall, the ANOVA revealed a significant main effect of treatment 
[F(3,45)=12.0, p<0.001] that was not accompanied by a main effect of administration 
condition [F(1,15)= 2.6, NS] or an interaction between the two factors [F(3,45)= 0.2, NS]. 
Post-hoc comparisons showed significant decrease in the number of nicotine infusions self-
administered following treatment with varenicline at 1.0 and 3.0 mg/kg (p<0.05 and 
p<0.001, respectively). In rats subjected to both alcohol-self-administration alone and in the 
co-administration group, varenicline did not modify the number of alcohol doses earned 
(main effect of treatment: [F(3,48)=0.6, NS], interaction [F(3,48)=1.9, NS], Figure 3). Overall, 
the ANOVA also revealed a significant main effect of the “co-administration” factor 
[F(1,16)= 7.9, p<0.05], suggesting that in the presence of nicotine, alcohol self-administration 
was reduced. This finding is in contrast with data reported in Figs 1C and 1D in which no 
difference in alcohol self-administration was observed between the co-administration and 
alcohol alone groups. This difference may be due to the fact that varenicline itself is a 
reinforcer and the presence of three drugs may result in a reduction in alcohol consumption.
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3.2 Nicotine self-administration in msP rats with or without access to alcohol in the two- 
bottle choice paradigm: Effect of varenicline
Overall, the ANOVA showed a robust main effect of varenicline treatment [F(3,66)=22.0, 
p<0.001] on nicotine self-administration. No main effect of alcohol exposure [F(1,22)=0.0, 
NS] or interactions between varenicline treatment and alcohol exposure [F(3,66)=0.8, NS] 
were observed. Post-hoc analysis showed a significant reduction in nicotine self-
administration at all the three doses tested (p<0.001, Figure 4). When the effect of 
varenicline was analysed against home-cage alcohol drinking (Figure 5) following operant 
nicotine self-administration sessions, the ANOVA revealed no effect of varenicline at both 2 
hours ([F(3,33)=0.6, NS] and 24 hours ([F(3,33)=2.5, NS]) post treatment. Food intake was 
also not affected by varenicline ([F(3,33)=1.41, NS]; data not shown).
4. DISCUSSION
In the present study, we examined the effect of varenicline, a nAchRs ligand, on the 
concurrent administration of nicotine and alcohol in marchigian sardinian alcohol-preferring 
rats. We found that while msP rats readily self-administered both alcohol and nicotine, there 
was an attenuation in nicotine self-administration in the presence of alcohol. Varenicline 
decreased operant nicotine self-administration as anticipated, but failed to decrease both 
operant and home-cage alcohol intake under co-administration conditions.
4.1 Nicotine and alcohol co-administration
To mimic the co-abuse of alcohol and nicotine that often occurs in humans (DiFranza and 
Guerrera, 1990; Miller and Gold, 1998), we used two distinct paradigms of alcohol and 
nicotine co-administration in this study. Firstly, both intravenous nicotine and oral alcohol 
were made simultaneously available in 60-min daily operant sessions, as originally 
described by Le et al (2010). Secondly, rats were trained to self-administer nicotine in daily 
120-min operant sessions, which was followed by access to 10% alcohol in the home-cage.
Results from our operant co-administration study indicate that msP rats readily self-
administered nicotine and alcohol concurrently. Interestingly, nicotine intake was 
significantly lowered in rats co-administering alcohol compared to those self-administering 
nicotine alone. This effect was limited to operant training sessions and became less robust 
during testing, perhaps due to the presence of varenicline on board along with alcohol and 
nicotine. Our findings are consistent, at least in part, with the studies of Le et al. where the 
authors evaluated the effect of concurrent access to nicotine and alcohol in heterogenous 
Wistar rats. While it is plausible that a decrease in nicotine self-administration in the 
presence of alcohol availability is due to the sedative or motor-impairing properties of 
alcohol as hypothesized by Le et al., a decrease in nicotine self-administration is also 
observed with concurrent access to cocaine (Manzardo et al., 2002). Thus, at least for 
nicotine, it appears that polydrug availability may lead to a decrement in the operant self-
administration of a single reinforcer. This hypothesis is generally in agreement with the 
theory of competition between multiple reinforcers, according to which the availability of an 
alternate reward may attenuate the demand for the primary reinforcer. For instance, 
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concurrent availability of a drug of abuse and a sweetened drink reduces demand for the 
drug (Carroll et al., 1991; Lenoir and Ahmed, 2008).
Contrary to the finding discussed above, results from co-administration studies where msP 
rats were allowed ad libitum access to 10% v/v ethanol in the home-cage following operant 
nicotine self-administration sessions indicate no changes in nicotine intake. This is likely 
due to procedural differences as rats in the two-bottle choice experiment did not consume 
alcohol and nicotine simultaneously.
4.2 Effect of varenicline on nicotine and alcohol co-administration
Varenicline is known to reduce nicotine and alcohol intake in both humans and rodents 
(Cippitelli et al., 2015c; Jorenby et al., 2006; Kamens et al., 2010; Litten et al., 2013; 
Steensland et al., 2007). Results from the present study demonstrate a robust reduction in 
nicotine consumption in accordance with previous preclinical and clinical evidence (Jorenby 
et al., 2006; Rollema et al., 2007). This decrease was observed regardless of concurrent 
consumption of alcohol. Surprisingly, we observed a lack of varenicline effect on alcohol 
self-administration in msP rats. While this finding differs from previous studies showing a 
reduction of alcohol consumption both in rodents and humans following varenicline 
administration (Fucito et al., 2011; Kamens et al., 2010; McKee et al., 2009; Mitchell et al., 
2012; Steensland et al., 2007), a lack of efficacy of varenicline on alcohol drinking has also 
been previously reported in both rodents and humans (Ginsburg and Lamb, 2013; Plebani et 
al., 2013; Randall et al., 2015). Moreover, in a recent place conditioning study varenicline 
was unable to prevent the expression of alcohol place preference, indicating a lack of drug 
efficacy in attenuating the motivational effects of alcohol-associated cues (Gubner et al., 
2015). For further confidence in our results, we also examined the effect of varenicline using 
a two-bottle free choice drinking procedure. Similar to the lack of effect of varenicline on 
operant alcohol intake, we found no effect of the drug on two-bottle free choice drinking of 
alcohol, excluding the possibility of a paradigm-dependent effect.
A possible explanation for the lack of effect of varenicline on alcohol intake is that this drug 
is not adequately bioavailable to bind to nACh receptors. However, this is unlikely since it 
has been documented that brain and plasma unbound concentrations of varenicline remain 
stable for at least 6 hours after oral administration (Rollema et al., 2010). In addition, the 
effect of varenicline on ethanol consumption in non-preferring rats is maintained for up to 6 
hours (Steensland et al., 2007). We also recently found that in heterogeneous Sprague-
Dawley rats, varenicline reduced both nicotine and alcohol self-administration when tested 
in an operant co-administration paradigm identical to the one used here (Cippitelli et al., 
2015c). Thus, it is unlikely that the lack of effect of varenicline on alcohol intake is due to 
bioavailability issues. However, it is seemingly likely that the effect of varenicline is 
dependent upon the rat strain and that msP rats may be less sensitive to the actions of the 
drug on alcohol intake.
The msP rat is an established animal model of excessive alcohol drinking, and has been 
hypothesized to represent a “phenocopy” of post-dependent animals (Ciccocioppo et al 
2006). MsP rats share similar neuroadaptations with heterogeneous rats following a history 
of alcohol intoxication. For instance, both animal models are characterized by dysregulation 
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of stress-mechanisms, upregulation of corticotropin releasing factor 1 receptors (CRF1 
receptor), altered response to the anxiolytic peptide nociception/orphanin FQ and enhanced 
emotional reactivity (Hansson et al., 2006; Heilig and Koob, 2007; Economidou et al., 
2008). Based upon these considerations it is tempting to speculate that altered expression, 
composition or function of nAChRs could contribute to shape the post-dependent state and 
possibly alter the innate predisposition to excessive drinking in msP rats, while 
simultaneously causing reduced sensitivity to the effect of varenicline in these animals. 
Previous work has shown that during selection for excessive drinking a few genetic traits 
have been segregated in msP rats. For instance it has been demonstrated that msP rats carry 
a mutation at the CRF1 receptor locus that confers increased sensitivity to the effects of 
CRF1 receptor antagonists (Ayanwuyi et al., 2013; Cippitelli et al., 2015a). Similar 
mechanisms might be at play in case of nAChRs, thus modulating the neurochemical, and 
subsequently behavioral response to drugs acting at these receptors. Future work aimed at 
determining the expression and function of nAChRs in reward-related brain structures in 
msP rats might provide an insight into this hypothesis. While the effects of varenicline have 
been examined in heavy drinking smokers or primary alcoholics (Erwin and Slaton, 2014) in 
clinical studies, patients were not selected based upon their genetic predisposition to alcohol 
abuse. Our results suggest that the efficacy of varenicline on alcohol drinking may be highly 
dependent on the genetics of the patient population treated.
4.3 Conclusion
We propose that rats genetically selected for high alcohol intake and preference, such as 
those from the msP line, are a useful tool to study the physiopathology of nicotine and 
alcohol co-abuse. Our results in msP rats demonstrate that treatment with varenicline 
reduces nicotine self-administration but does not alter alcohol consumption in these animals. 
While further studies are warranted to determine the receptor mechanisms underlying lack 
of effect of varenicline on alcohol intake, the present results may have important clinical 
implications and may raise important pharmacogenetic considerations on whether the 
efficacy of varenicline on alcohol abuse is limited only to a sub-set and does not extend to 
all patient populations.
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Highlights
• Alcohol and nicotine are largely co-abused
• Varenicline is a first-line treatment option for nicotine dependence
• Varenicline attenuates nicotine self-administration in alcohol-preferring animals
• Varenicline fails to reduce ethanol intake in alcohol-preferring animals
• When alcohol and nicotine are co-used, varenicline’s effect is restricted to 
nicotine
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Figure 1. 
Self-administration of 10% (v/v) alcohol and 30 μg/kg/inf nicotine in msP rats trained to co-
self-administer both drugs during the same operant session or trained to lever press for only 
nicotine or only alcohol. (A) Nicotine lever pressing is higher in the msP group with access 
to only nicotine (N=9) than the group with access to both reinforcers (N=8). (B) Nicotine 
infusions during the last 3 sessions differed between the only nicotine and the co-
administration group (***p<0.001). (C) Alcohol self-administration did not significantly 
differ between the group pressing for alcohol alone (N=10) and the co-administration group 
(N=8). (D) Alcohol rewards during the last 3 sessions were not altered between the only 
alcohol and the co-administration group. Data are expressed as the mean (± SEM) number of 
infusions (nicotine) or rewards (alcohol) earned by rats during the last three 60-min self-
administration sessions. For detailed statistics see “Results”.
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Figure 2. 
Effect of varenicline (0.0, 0.3, 1.0 and 3.0 mg/kg) on nicotine (30 μg/kg/inf) taking- 
behavior in msP rats subjected to nicotine/alcohol co-administration (N=8) and nicotine self-
administration only (N=9). After a stable pattern of alcohol and/or nicotine self-
administration was reached, animals were treated with varenicline, according to a latin 
square design. Varencline was administered p.o. 30 minutes before the beginning of test 
sessions. The day after the test, animals were given a day off and self-administration 
baseline was re-established the following day. Results showed that varenicline doses of 1.0 
and 3.0 mg/kg significantly reduced nicotine lever pressing in both groups. Results are 
expressed as the mean (± SEM) number of infusions in 60 min. *p<0.05, ***p<0.001 
difference from vehicle-treated rats (0.0 mg/kg). For detailed statistics see “Results”.
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Figure 3. 
Effect of varenicline (0.0, 0.3, 1.0 and 3.0 mg/kg) on 10% alcohol-maintained lever pressing 
in msP rats subjected to nicotine/alcohol co-administration (N=8) and alcohol self-
administration alone (N=10). Briefly, after a stable pattern of nicotine and/or alcohol self-
administration was reached, animals were treated with varenicline, according to a within 
subject design. Varencline was administered p.o. 30 minutes before the beginning of test 
sessions. The day after the test, animals were given a day off and self-administration 
baseline was reestablished the following day. Statistical analysis of the number of alcohol 
rewards demonstrated that varenicline failed to alter alcohol self-administration. Results are 
expressed as the mean (± SEM) number of rewards in 60 min. For detailed statistics see 
“Results”.
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Figure 4. 
Effect of varenicline (0.0, 0.3, 1.0 and 3.0 mg/kg) on nicotine self-administration in msP rats 
exposed (N=12) and non-exposed (N=12) to 22-h 10% (v/v) alcohol access in their home-
cages (two bottle choice paradigm). Varenicline, given 30 minutes before the operant 
nicotine 2-hours sessions, at all three doses tested significantly reduced nicotine lever 
pressing in alcohol exposed as well as non-exposed groups. Values represent the mean 
(±S.E.M) number of nicotine infusions. ***p<0.001 difference from vehicle-treated animals 
(0.0 mg/kg). For detailed statistics see “Results”.
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Figure 5. 
Effect of varenicline (0.0, 0.3, 1.0 and 3.0 mg/kg) on 10% (v/v) alcohol drinking assessed by 
the two-bottle free choice drinking paradigm (N=12). Drinking of msP animals was not 
affected by any dose of varenicline at 2-h from the beginning of alcohol exposure. Results 
represent the mean (±S.E.M) alcohol intake expressed as g/kg. For detailed statistics see 
“Results”.
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